Compare R & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | BMRN |
|---|---|---|
| Founded | 1933 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.4B |
| IPO Year | 1994 | 1999 |
| Metric | R | BMRN |
|---|---|---|
| Price | $260.79 | $69.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $238.56 | $88.22 |
| AVG Volume (30 Days) | 315.7K | ★ 1.9M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 5.71 | 0.77 |
| Revenue | ★ $12,665,000,000.00 | $1,313,646,000.00 |
| Revenue This Year | $5.00 | $15.02 |
| Revenue Next Year | $5.05 | $12.23 |
| P/E Ratio | ★ $45.60 | $89.43 |
| Revenue Growth | 0.23 | ★ 17.62 |
| 52 Week Low | $157.77 | $49.26 |
| 52 Week High | $284.25 | $69.27 |
| Indicator | R | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 78.49 |
| Support Level | $255.17 | $51.07 |
| Resistance Level | $281.16 | N/A |
| Average True Range (ATR) | 6.42 | 1.99 |
| MACD | -0.64 | 0.82 |
| Stochastic Oscillator | 41.99 | 90.13 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.